Krause v. Integra LifeSciences Corporation

CourtDistrict Court, D. Minnesota
DecidedJuly 11, 2025
Docket0:24-cv-04339
StatusUnknown

This text of Krause v. Integra LifeSciences Corporation (Krause v. Integra LifeSciences Corporation) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Krause v. Integra LifeSciences Corporation, (mnd 2025).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA

SUSAN KRAUSE, Case No. 24-cv-4339 (LMP/ECW)

Plaintiff,

v. ORDER DENYING DEFENDANT’S MOTION TO TRANSFER INTEGRA LIFESCIENCES CORPORATION,

Defendant.

Jonathan D. Miller, Debra L. Weiss, and Anthony W. Joyce, Meagher & Geer, P.L.L.P., Minneapolis, MN, for Plaintiff.

C.J. Schoenwetter, Bowman & Brooke LLP, Minneapolis, MN; John Thomas McDonald, Reed Smith LLP, Princeton, NJ; and Joseph J. Mammone, Jr., Reed Smith LLP, Dallas, TX, for Defendant.

Plaintiff Susan Krause (“Krause”) alleges that her former employer, Defendant Integra LifeSciences Corporation (“Integra”), discriminated against her because she engaged in whistleblower activity and because of her sex, retaliated against her because she opposed the alleged discrimination, created a hostile work environment, intentionally inflicted emotional distress on her, and defamed her. ECF No. 8 ¶¶ 81–132. All of Krause’s claims arise under Minnesota law. See generally id. Integra, a New Jersey company, moves to transfer venue to the U.S. District Court for the District of New Jersey. ECF No. 37. Because Integra does not meet its burden to show that transfer is appropriate, the Court denies the motion. BACKGROUND Krause worked for Integra from 2021 to 2024 as its Corporate Vice President and

Chief Quality Officer (“CQO”). ECF No. 8 ¶ 7. Integra is a “global medical technology company” whose principal place of business is in New Jersey, id. ¶¶ 2, 8, and which has 16 offices worldwide, yet none in Minnesota, ECF No. 49 ¶ 6. In her role as CQO, Krause oversaw product manufacturing at “over a dozen sites.” ECF No. 8 ¶ 11. Integra offered Krause employment on May 18, 2021. ECF No. 40-1 at 3–4. On that day, Integra’s Chief Human Resources Officer emailed Krause and extended an offer

of employment, stating: Susan,

Attached please find the offer letter we discussed and the referenced confidentiality agreement. We are thrilled that you will be joining us and look forward to working with you and your many contributions. Please review the offer letter, and contact me any time with questions you have.

Congratulations and we look forward to your response to the offer.

Id. The email, as noted, attached both an offer letter and document titled “Confidentiality and Invention Disclosure and Non-Compete Agreement” (hereinafter the “Confidentiality Agreement”). Id. The offer letter, in part, contained the following provision: This offer is contingent upon satisfactory completion of Integra’s pre- employment screening process, including a background check and references. This offer is also contingent upon your signing the attached agreement. All employees are required to sign this document. Please review, sign and date the attached agreement and return it along with a copy of your signed offer letter. The original agreement should be sent to the Human Resources Department along with the other administrative forms in the new hire kit provided to you. If you have questions regarding the agreement, please contact the Human Resources Department. If you do not agree with the terms of this document, this offer of employment, including all of its terms, will be rescinded.

ECF No. 53-1 at 11 (emphasis added). The Confidentiality Agreement, in turn, contained a non-compete agreement as well as an agreement that Krause would not disclose company secrets. See generally id. at 3–9. The Confidentiality Agreement concluded with the following provision: I agree that the validity, enforceability, construction and interpretation of this Agreement shall be governed by the laws of the State of New Jersey, without regard to its conflict of law rules. I also agree and consent that any and all litigation between Integra and me relating to this Agreement will take place exclusively in the State of New Jersey, and I consent to the jurisdiction and venue of the federal and/or state courts in the State of New Jersey.

Id. at 8. On May 21, Krause requested three alterations to the offer letter but did not otherwise mention the Confidentiality Agreement. ECF No. 40-1 at 3. On May 22, Integra agreed to two of the three alterations and attached a revised offer letter. Id. at 2. The revised offer letter contained identical language as the original conditioning Krause’s employment on her “signing the attached agreement.” ECF No. 53-3 at 3. The May 22 email, however, did not attach (or reattach as it may be) the Confidentiality Agreement. ECF No. 40-1 at 2. On May 22, Krause signed the revised offer letter and emailed it back to Integra. ECF No. 49-1 at 1; ECF No. 53-3 at 4. Integra hired Krause as a full-time remote employee, working primarily from Minnesota, but she traveled frequently. ECF No. 49 at 1. In her role as CQO, Krause was

responsible for Integra’s 600-person quality department, which oversaw more than 25,000 products manufactured at sites across the country. ECF No. 8 ¶ 11. Upon employment, Krause was immediately tasked with assisting Integra’s facility in Boston, Massachusetts, to come into compliance with FDA regulations. Id. ¶ 15. But Krause alleges that Integra’s executives stymied her attempts to report or to resolve quality control issues at the Boston facility and at other locations throughout her three years of employment. Id. ¶¶ 12–13.

Specifically, she alleges that CEO Jan De Witte (“De Witte”) and Chief Legal Officer Eric Schwartz (“Schwartz”) “threatened, yelled at, used profanity toward, and verbally abused” her in retaliation for her years-long efforts to report quality issues at Integra’s production locations in Massachusetts, Pennsylvania, and New Jersey. Id. ¶¶ 12– 22, 63–72. She also alleges that De Witte and Schwartz “repeatedly rebuffed” her attempts

to bring such information to Integra’s Board of Directors, id. ¶ 36, and generally encouraged her to circumvent FDA regulation, id. ¶ 39. Because of the hostile work environment created by the executives, Krause resigned on March 11, 2024. Id. ¶ 72. Krause alleges that De Witte thereafter defamed her during an earnings call by implying that he fired Krause to solve the company’s quality control issues. Id. ¶ 73.

Krause filed her complaint in Minnesota state court on November 8, 2024, and Integra thereafter removed it to this Court pursuant to 28 U.S.C. §§ 1332, 1441, and 1446, based on diversity jurisdiction. ECF No. 1. Now, Integra moves to transfer venue to the District of New Jersey pursuant to 28 U.S.C. § 1404(a). ECF No. 37. Integra argues that although Krause resides in Minnesota and worked remotely for Integra from Minnesota, the case would be more conveniently litigated in New Jersey, where Integra is

headquartered. ECF No. 38 at 1–2. Integra further argues that Krause’s employment agreement contains a valid and enforceable forum-selection clause which requires the Court to transfer the case to New Jersey. Id. at 10. Krause argues that Integra fails to meet its burden to show that the case should be transferred under Section 1404(a) and that the forum-selection clause is inapplicable to her claims. ECF No. 48 at 2–3. ANALYSIS

Krause originally filed this action in Minnesota state court, but Integra removed it to this Court pursuant to 28 U.S.C. § 1441(b), based on the diversity of citizenship between the parties. ECF No. 1, see also 28 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Apple, Inc.
602 F.3d 909 (Eighth Circuit, 2010)
Gulf Oil Corp. v. Gilbert
330 U.S. 501 (Supreme Court, 1947)
Van Dusen v. Barrack
376 U.S. 612 (Supreme Court, 1964)
Stewart Organization, Inc. v. Ricoh Corp.
487 U.S. 22 (Supreme Court, 1988)
In Re TS Tech USA Corp.
551 F.3d 1315 (Federal Circuit, 2008)
Holden Farms, Inc. v. Hog Slat, Inc.
347 F.3d 1055 (Eighth Circuit, 2003)
Brookfield Trade Center, Inc. v. County of Ramsey
584 N.W.2d 390 (Supreme Court of Minnesota, 1998)
Valspar Refinish, Inc. v. Gaylord's, Inc.
764 N.W.2d 359 (Supreme Court of Minnesota, 2009)
Thomas B. Olson & Associates, P.A. v. Leffert, Jay & Polglaze, P.A.
756 N.W.2d 907 (Court of Appeals of Minnesota, 2008)
Phillips v. Audio Active Ltd.
494 F.3d 378 (Second Circuit, 2007)
Martinez v. Bloomberg LP
740 F.3d 211 (Second Circuit, 2014)
In re: Union Electric Company v.
787 F.3d 903 (Eighth Circuit, 2015)
Peter Weber v. Pact XPP Technologies, AG
811 F.3d 758 (Fifth Circuit, 2016)
Ina Collins v. Mary Kay Inc
874 F.3d 176 (Third Circuit, 2017)
Reading Health System v. Bear Stearns Co Inc
900 F.3d 87 (Third Circuit, 2018)
Medtronic Sofamor Danek, Inc. v. Patrick B. Gannon
913 F.3d 704 (Eighth Circuit, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Krause v. Integra LifeSciences Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/krause-v-integra-lifesciences-corporation-mnd-2025.